$277.62
+4.97
(+1.82%)▲
2.92%
Downside
Day's Volatility :5.59%
Upside
2.75%
51.74%
Downside
52 Weeks Volatility :63.43%
Upside
24.23%
Period | Ufp Technologies Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -9.03% | -2.1% | 0.0% |
6 Months | 6.3% | 4.9% | 0.0% |
1 Year | 89.99% | 16.0% | 0.0% |
3 Years | 319.73% | 10.0% | -26.4% |
Market Capitalization | 2.0B |
Book Value | $40.42 |
Earnings Per Share (EPS) | 6.4 |
PE Ratio | 41.72 |
PEG Ratio | 0.0 |
Wall Street Target Price | 378.5 |
Profit Margin | 11.87% |
Operating Margin TTM | 17.36% |
Return On Assets TTM | 9.69% |
Return On Equity TTM | 17.37% |
Revenue TTM | 417.5M |
Revenue Per Share TTM | 54.56 |
Quarterly Revenue Growth YOY | 10.100000000000001% |
Gross Profit TTM | 90.3M |
EBITDA | 75.4M |
Diluted Eps TTM | 6.4 |
Quarterly Earnings Growth YOY | 0.13 |
EPS Estimate Current Year | 7.08 |
EPS Estimate Next Year | 8.27 |
EPS Estimate Current Quarter | 1.53 |
EPS Estimate Next Quarter | 1.75 |
What analysts predicted
Upside of 36.34%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 190.5M | ↑ 28.82% |
Net Income | 14.3M | ↑ 55.39% |
Net Profit Margin | 7.51% | ↑ 1.28% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 198.4M | ↑ 4.16% |
Net Income | 19.8M | ↑ 38.01% |
Net Profit Margin | 9.96% | ↑ 2.45% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 179.4M | ↓ 9.58% |
Net Income | 13.4M | ↓ 32.31% |
Net Profit Margin | 7.45% | ↓ 2.51% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 206.3M | ↑ 15.02% |
Net Income | 15.9M | ↑ 18.83% |
Net Profit Margin | 7.7% | ↑ 0.25% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 353.8M | ↑ 71.48% |
Net Income | 41.8M | ↑ 163.06% |
Net Profit Margin | 11.81% | ↑ 4.11% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 400.1M | ↑ 13.08% |
Net Income | 44.9M | ↑ 7.5% |
Net Profit Margin | 11.23% | ↓ 0.58% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 97.8M | ↑ 7.14% |
Net Income | 9.7M | ↑ 15.09% |
Net Profit Margin | 9.96% | ↑ 0.69% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 100.0M | ↑ 2.34% |
Net Income | 11.9M | ↑ 22.01% |
Net Profit Margin | 11.88% | ↑ 1.92% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 100.8M | ↑ 0.75% |
Net Income | 11.7M | ↓ 1.59% |
Net Profit Margin | 11.6% | ↓ 0.28% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 101.5M | ↑ 0.71% |
Net Income | 11.6M | ↓ 0.74% |
Net Profit Margin | 11.44% | ↓ 0.16% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 105.0M | ↑ 3.46% |
Net Income | 12.7M | ↑ 9.35% |
Net Profit Margin | 12.09% | ↑ 0.65% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 110.2M | ↑ 4.92% |
Net Income | 13.6M | ↑ 6.77% |
Net Profit Margin | 12.3% | ↑ 0.21% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 189.6M | ↑ 37.18% |
Total Liabilities | 49.1M | ↑ 239.02% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 188.8M | ↓ 0.44% |
Total Liabilities | 26.8M | ↓ 45.53% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 203.2M | ↑ 7.65% |
Total Liabilities | 26.3M | ↓ 1.7% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 334.1M | ↑ 64.43% |
Total Liabilities | 139.7M | ↑ 430.9% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 377.5M | ↑ 12.99% |
Total Liabilities | 140.0M | ↑ 0.22% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 404.1M | ↑ 7.04% |
Total Liabilities | 118.0M | ↓ 15.68% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 390.8M | ↑ 3.51% |
Total Liabilities | 144.3M | ↑ 3.07% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 398.0M | ↑ 1.85% |
Total Liabilities | 137.7M | ↓ 4.57% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 399.8M | ↑ 0.46% |
Total Liabilities | 127.4M | ↓ 7.47% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 404.1M | ↑ 1.08% |
Total Liabilities | 118.0M | ↓ 7.36% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 407.7M | ↑ 0.88% |
Total Liabilities | 112.7M | ↓ 4.56% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 422.4M | ↑ 3.61% |
Total Liabilities | 112.2M | ↓ 0.39% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 21.3M | ↑ 22.04% |
Investing Cash Flow | -82.3M | ↑ 693.53% |
Financing Cash Flow | 26.3M | ↓ 5630.32% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 31.2M | ↑ 46.48% |
Investing Cash Flow | -5.8M | ↓ 92.99% |
Financing Cash Flow | -25.0M | ↓ 194.98% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 25.0M | ↓ 19.83% |
Investing Cash Flow | -4.3M | ↓ 26.2% |
Financing Cash Flow | -285.0K | ↓ 98.86% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.3M | ↓ 42.91% |
Investing Cash Flow | -101.5M | ↑ 2281.11% |
Financing Cash Flow | 74.0M | ↓ 26082.11% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 17.7M | ↑ 24.14% |
Investing Cash Flow | 1.3M | ↓ 101.27% |
Financing Cash Flow | -25.9M | ↓ 134.97% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.7M | ↓ 90.37% |
Investing Cash Flow | -2.2M | ↓ 26.55% |
Financing Cash Flow | 2.6M | ↓ 112.41% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 8.9M | ↑ 415.21% |
Investing Cash Flow | -2.8M | ↑ 27.24% |
Financing Cash Flow | -7.3M | ↓ 385.34% |
Sell
Neutral
Buy
Ufp Technologies Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Ufp Technologies Inc | -5.56% | 6.3% | 89.99% | 319.73% | 551.19% |
Stryker Corporation | 4.54% | 12.8% | 32.62% | 35.95% | 78.95% |
Boston Scientific Corp. | -1.09% | 15.26% | 58.34% | 96.75% | 104.05% |
Edwards Lifesciences Corp. | 3.13% | -20.63% | 0.66% | -42.46% | -13.89% |
Abbott Laboratories | 5.29% | 12.27% | 24.84% | -8.13% | 44.25% |
Medtronic Plc | 2.05% | 10.16% | 22.68% | -25.37% | -15.94% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Ufp Technologies Inc | 41.72 | 41.72 | 0.0 | 7.08 | 0.17 | 0.1 | NA | 40.42 |
Stryker Corporation | 38.19 | 38.19 | 2.49 | 12.05 | 0.19 | 0.07 | 0.01 | 52.87 |
Boston Scientific Corp. | 69.44 | 69.44 | 1.53 | 2.46 | 0.09 | 0.05 | NA | 13.85 |
Edwards Lifesciences Corp. | 28.62 | 28.62 | 6.15 | 2.53 | 0.22 | 0.12 | NA | 12.35 |
Abbott Laboratories | 36.05 | 36.05 | 2.2 | 4.67 | 0.14 | 0.06 | 0.02 | 22.6 |
Medtronic Plc | 30.05 | 30.05 | 1.65 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Ufp Technologies Inc | Buy | $2.0B | 551.19% | 41.72 | 11.87% |
Stryker Corporation | Buy | $138.5B | 78.95% | 38.19 | 16.34% |
Boston Scientific Corp. | Buy | $123.7B | 104.05% | 69.44 | 11.26% |
Edwards Lifesciences Corp. | Buy | $40.7B | -13.89% | 28.62 | 65.86% |
Abbott Laboratories | Buy | $205.7B | 44.25% | 36.05 | 13.99% |
Medtronic Plc | Buy | $116.1B | -15.94% | 30.05 | 12.06% |
Insights on Ufp Technologies Inc
Revenue is up for the last 7 quarters, 91.23M → 110.17M (in $), with an average increase of 3.1% per quarter
Netprofit is up for the last 3 quarters, 11.60M → 13.55M (in $), with an average increase of 7.4% per quarter
BlackRock Inc
Neuberger Berman Group LLC
Vanguard Group Inc
Renaissance Technologies Corp
Morgan Stanley - Brokerage Accounts
State Street Corp
ufp technologies is a producer of innovative custom-engineered components, products, and specialty packaging. founded in 1963 and headquartered in newburyport, massachusetts, our company has pioneered a long list of processes and applications, has a large portfolio of active patents, and holds proprietary positions on many advanced materials from leading global suppliers. with a deep and accomplished engineering team, ufp technologies is a critical link in the value chain between raw material suppliers and oems. our team acts as an extension of customers' in-house research, engineering and manufacturing groups, working closely with them to solve their most complex product and packaging challenges. using foams, plastics, composites, and natural fiber materials, we design and manufacture a vast range of solutions primarily for six target markets including medical, automotive, aerospace & defense, electronics, consumer and industrial.
Organization | Ufp Technologies Inc |
Employees | 3093 |
CEO | Mr. R. Jeffrey Bailly |
Industry | Process Industries |
Cullen/frost Bankers, Inc.
$277.62
+1.82%
United States Steel Corp.
$277.62
+1.82%
Ishares Long-term Corporate Bond Etf
$277.62
+1.82%
Alamo Group Inc
$277.62
+1.82%
Stevanato Group S.p.a.
$277.62
+1.82%
Nnn Reit Inc.
$277.62
+1.82%
Sasol Ltd.
$277.62
+1.82%
Eldorado Gold Corporation
$277.62
+1.82%
Krystal Biotech Inc
$277.62
+1.82%